secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001728117-26-000018
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio reports 2025 net loss $170.4M; seralutinib Phase 3 narrowly missed primary endpoint
--------------------------------------------------------------------------------

- PROSERA Phase 3 in PAH showed placebo-adjusted 6MWD +13.3 meters but missed prespecified statistical alpha of 0.025 (p=0.0320).
- Enrollment in Phase 3 SERANATA (PH-ILD) paused; Company evaluating implications and plans FDA Type C meeting in June 2026.
- Implemented reduction in force and cost-containment measures to align resources with near-term priorities.
- Cash, equivalents and marketable securities $136.9M at Dec 31, 2025; expected to fund operations into Q1 2027.
- Net loss for FY2025 was $170.4M ($0.75 per share) compared to $56.5M ($0.25 per share) in FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000018/0001728117-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811726000018/goss-20260317.htm
  HTML page:      https://secwatch.observer/filing/0001728117-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer